Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 studyMichael J. Overman, Thierry André, Andrew Hill et al.|The Lancet Oncology|2017Cited by 2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal CancerMichael J. Overman, Thierry André, Sara Lonardi et al.|Journal of Clinical Oncology|2018Cited by 2.1k
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142Thierry André, Michael J. Overman, Sara Lonardi et al.|Annals of Oncology|2022Cited by 253
Endovascular Proximal Forearm Arteriovenous Fistula for Hemodialysis Access: Results of the Prospective, Multicenter Novel Endovascular Access Trial (NEAT)Charmaine E. Lok, David W. Johnson, Dheeraj K. Rajan et al.|American Journal of Kidney Diseases|2017Cited by 143
Renal artery stent revascularization with embolic protection in patients with ischemic nephropathyAndrew Holden, Helen Pilmore, Andrew Hill et al.|Kidney International|2006Cited by 128